Malignant pleural mesothelioma: The disdained member of thoracic oncology!

Divya Khosla, Pawan Kumar Singh, Bharath A Chhabria, Vaishali Kataria, Navneet Singh, Rakesh Kapoor
{"title":"Malignant pleural mesothelioma: The disdained member of thoracic oncology!","authors":"Divya Khosla, Pawan Kumar Singh, Bharath A Chhabria, Vaishali Kataria, Navneet Singh, Rakesh Kapoor","doi":"10.5493/wjem.v14.i3.91739","DOIUrl":null,"url":null,"abstract":"<p><p>Pleural mesothelioma is a very aggressive malignancy that arises from the pleural mesothelial cell lining and is linked strongly to prior asbestos exposure. The ban on asbestos has helped to lower the incidence, but in developing countries like India, it is expected to rise. It has an extended latency period usually progressing over decades and presents with nonspecific symptoms. It has a median survival ranging between 10-22 months. The diagnosis of malignant pleural mesothelioma is challenging and is done using computed tomography (CT), magnetic resonance imaging, or positron emission tomography-CT, with the last two predicting the resectability of the tumor better than CT alone. A pleural biopsy along with an array of immunohistochemical markers, such as p16, BRCA1 associated protein 1, and claudin-4, are required for a definitive diagnosis. Several genetic alterations have prognostic significance as well. The current histological subtype identification is indispensable for decision making because of the new therapeutic avenues being explored. The combination of nivolumab and ipilimumab-based immunotherapy outperformed platinum and pemetrexed-based chemotherapy in terms of survival benefit and improved quality of life especially for non-epithelioid subtypes. However, the latter continues to be a robust treatment option for patients with the epithelioid subtype. Surgery is recommended for resectable cases with radiotherapy being indicated in neoadjuvant, adjuvant, and palliative settings along with systemic treatment. This review article provides an overview of epidemiology, etiology, clinical manifestations, diagnostic approaches (including immunohistochemical and genetic markers), staging, and multidisciplinary approaches to current treatment for malignant pleural mesothelioma using surgery, chemotherapy, immunotherapy, and radiotherapy. It also sheds light on some recent studies (EMPHACIS, CALGB30901, Checkmate-743, <i>etc.</i>) that have led to significant developments in recent years with clinically meaningful results.</p>","PeriodicalId":75340,"journal":{"name":"World journal of experimental medicine","volume":"14 3","pages":"91739"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11372740/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of experimental medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5493/wjem.v14.i3.91739","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Pleural mesothelioma is a very aggressive malignancy that arises from the pleural mesothelial cell lining and is linked strongly to prior asbestos exposure. The ban on asbestos has helped to lower the incidence, but in developing countries like India, it is expected to rise. It has an extended latency period usually progressing over decades and presents with nonspecific symptoms. It has a median survival ranging between 10-22 months. The diagnosis of malignant pleural mesothelioma is challenging and is done using computed tomography (CT), magnetic resonance imaging, or positron emission tomography-CT, with the last two predicting the resectability of the tumor better than CT alone. A pleural biopsy along with an array of immunohistochemical markers, such as p16, BRCA1 associated protein 1, and claudin-4, are required for a definitive diagnosis. Several genetic alterations have prognostic significance as well. The current histological subtype identification is indispensable for decision making because of the new therapeutic avenues being explored. The combination of nivolumab and ipilimumab-based immunotherapy outperformed platinum and pemetrexed-based chemotherapy in terms of survival benefit and improved quality of life especially for non-epithelioid subtypes. However, the latter continues to be a robust treatment option for patients with the epithelioid subtype. Surgery is recommended for resectable cases with radiotherapy being indicated in neoadjuvant, adjuvant, and palliative settings along with systemic treatment. This review article provides an overview of epidemiology, etiology, clinical manifestations, diagnostic approaches (including immunohistochemical and genetic markers), staging, and multidisciplinary approaches to current treatment for malignant pleural mesothelioma using surgery, chemotherapy, immunotherapy, and radiotherapy. It also sheds light on some recent studies (EMPHACIS, CALGB30901, Checkmate-743, etc.) that have led to significant developments in recent years with clinically meaningful results.

恶性胸膜间皮瘤:胸腔肿瘤学中被轻视的一员!
胸膜间皮瘤是一种侵袭性很强的恶性肿瘤,它产生于胸膜间皮细胞内膜,与以前接触石棉有很大关系。石棉禁令有助于降低发病率,但在印度等发展中国家,预计发病率还会上升。这种疾病的潜伏期较长,通常会持续数十年,并伴有非特异性症状。中位生存期为 10-22 个月。恶性胸膜间皮瘤的诊断极具挑战性,需要通过计算机断层扫描(CT)、磁共振成像或正电子发射断层扫描(Positron emission tomography-CT)来完成。明确诊断需要胸膜活检和一系列免疫组化标记物,如 p16、BRCA1 相关蛋白 1 和 claudin-4。一些基因改变也具有预后意义。由于正在探索新的治疗途径,目前的组织学亚型鉴定对于决策是不可或缺的。基于 nivolumab 和 ipilimumab 的联合免疫疗法在生存获益和生活质量改善方面优于基于铂和培美曲塞的化疗,尤其是对非上皮样亚型。然而,对于上皮样亚型患者来说,后者仍然是一种强有力的治疗选择。建议对可切除病例进行手术治疗,同时在新辅助治疗、辅助治疗和姑息治疗中配合放疗和全身治疗。这篇综述文章概述了恶性胸膜间皮瘤的流行病学、病因学、临床表现、诊断方法(包括免疫组化和遗传标记)、分期,以及目前使用手术、化疗、免疫治疗和放疗进行治疗的多学科方法。本书还介绍了一些最新研究(EMPHACIS、CALGB30901、Checkmate-743 等),这些研究近年来取得了重大进展,并产生了有临床意义的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信